Kuros Biosciences AG

EQS-Adhoc: Kuros Bioscience's Shareholders Approve All Resolutions

EQS Group-Ad-hoc: Kuros Biosciences AG / Key word(s): AGM/EGM
Kuros Bioscience's Shareholders Approve All Resolutions

16.06.2016 / 14:38
Release of an ad hoc announcement pursuant to Art. 53 KR.
The issuer is solely responsible for the content of this announcement.

Kuros Bioscience's Shareholders Approve All Resolutions

Schlieren (Zurich), Switzerland, June 16, 2016 - Kuros Biosciences Ltd ("Kuros")
today announced that its shareholders approved all resolutions at the Annual
Shareholders' Meeting 2016. In particular, they voted with a large majority for
the proposed reverse stock split at the ratio of 100 to 1 and therefore the
necessary changes of the articles of association. The reverse stock split is
expected to simplify the trading and increase the shares' attractiveness for
investors. The first trading day of the new shares is expected to be June 23,
2016. The shareholders' meeting further resolved on an authorized capital
increase which the Board intends to partially use for a quick and flexible
raising of capital (including private placements), Shareholders also elected
Leanna Caron as new member of the Board of Directors.

The Annual Shareholders' Meeting of Kuros took place at the Company's
headquarters in Schlieren/Zurich (Switzerland). It was attended by 77
shareholders. 237'200'269 shares or 46.65% of a total of 508'432'244 shares were

For further information, please contact:
Kuros Biosciences Ltd
Harry Welten, MBA
Chief Financial Officer
Tel: +41 44 733 46 46

About Kuros Biosciences Ltd

Kuros Biosciences Ltd is focused on the development of innovative products for
tissue repair and regeneration and is located in Schlieren (Zurich),
Switzerland. The Company is listed according to the International Reporting
Standard on the SIX Swiss Exchange Ltd under the symbol KURN. Information
regarding Kuros is available atwww.kuros.ch.

Forward Looking Statements
This media release contains certain forward-looking statements that involve
risks and uncertainties that could cause actual results to be materially
different from historical results or from any future results expressed or
implied by such forward-looking statements. You are urged to consider statements
that include the words "will" or "expect" or the negative of those words or
other similar words to be uncertain and forward-looking. Factors that may cause
actual results to differ materially from any future results expressed or implied
by any forward-looking statements include scientific, business, economic and
financial factors, Against the background of these uncertainties, readers should
not rely on forward-looking statements. The Company assumes no responsibility
for updating forward-looking statements or adapting them to future events or


End of ad hoc announcement
Additional features:

Document title: Kuros AGM2016

16.06.2016 News transmitted by Tensid EQS AG. www.eqs.com

The issuer is responsible for the contents of the release.

Language: English

Company:  Kuros Biosciences AG

          Wagistrasse 25

          8952  Schlieren


Phone:    +41 44 733 4747

Fax:      +41 44 733 4740


Internet: www.kuros.ch

ISIN:     CH0011025217

Valor:    -

Listed:   Foreign Exchange(s) SIX

End of News EQS Group News Service
472175  16.06.2016 

Weitere Meldungen: Kuros Biosciences AG

Das könnte Sie auch interessieren: